Table 2.

Major characteristics of the include study.

Study ID	Study type	Location	Participants Characteristics					BNP measurement method	References
			Male (%)	Female (%)	Age	Case	Control
Funayama 2011	Case-Control	Japan	62.2	37.8	68.5 ± 10.5	HF	Healthy	NR	[8]
Girerd 2022	Rct	USA	76	24	67.55 ± 9.95	HF	HF re-hospitalization with lower symptoms	NR	[9]
Chetran 2022	Case-Control	Romania	63.8	36.3	65.18 ± 12.98	AHF	ambulatory without HF	CL-EIA	[14]
Johansson 2022	Case-Control	Sweden	36.3	63.7	78.3 ± 5.1	HFpEF	Healthy	NR	[10]
Kang 2017	Case-Control	China	35.4	64.6	64.05 ± 10.35	SHF	No SHF	ECLIA	[15]
Kanukurti 2020	Cross-Sectional Study	India	52	47	57 ± 0.165	HFpEF	Healthy	ECLIA	[16]
Sultana 2010	Case-Control	Bangladesh	56	44	39 ± 30	HF	Healthy	MEIA	[11]
Sutter 2015	Cohort Case-Control	Belgium	100	0	50 ± 3	HF/CHD	Free from coronary event	ECLA	[12]
Yu 2017	Case-Control	China	61.7	38.3	63.65 ± 7.85	CHF	Healthy	ELISA	[13]

CHD = coronary heart disease, CHF = coronary heart failure, CL-EIA = chemiluminiscence enzyme immune assay, ECLA = electrochemiluminiscence assay, ECLIA = electrochemiluminescence immunoassay, ELISA = enzyme-linked immunosorbent assay, HFpEF = heart failure with preserved ejection factor, MEIA = microparticle enzyme immunoassay, NR = not reported, SHF = systolic heart failure.